Zhixiang Jintai (688443.SH): Marketing application for Telikibart Injection for chronic rhinosinusitis with nasal polyps accepted

Zhixiang Jintai (688443.SH) announced that recently, the company's Telikibart Injection (GR1802 Injection) for the indication of chronic rhinosinusitis with nasal polyps reached the primary endpoint in its Phase III clinical trial. The company submitted a new drug marketing application for this indication to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) and the application has been accepted. Telikibart Injection (GR1802 Injection) is a recombinant fully human anti-IL-4R monoclonal antibody independently developed by the company, targeting IL-4R. Telikibart Injection can specifically bind to human IL-4R on the cell surface, blocking the binding of IL-4 and IL-13 to IL-4R, inhibiting downstream STAT6 phosphorylation, and suppressing CD23 upregulation, thereby inhibiting the Th2-type inflammatory response mediated by IL-4 or IL-13.